

Provisional 2024 EPHMRA ATC Developments

The following new class structures were voted on by EPHMRA/Intellus in May/June 2023 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2024 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2023. The new structures then come into effect from the beginning of 2024.

Drugs for constipation

New fourth level class in A6A (Drugs for constipation) for peripheral opioid receptor antagonist laxatives (currently in A6A9).

A6A5	Peripheral opioid antagonist laxatives
	Includes products containing peripheral opioid receptor antagonist laxatives for the treatment of opioid-induced constipation (OIC). Substances include methylnaltrexone, naldemedine, naloxegol, etc. Products containing naloxone for opioid dependence are classified in N7F.

JAK inhibitors – cancer-specific

New fourth level class within L1H (Protein kinase inhibitor antineoplastics) for products containing JAK inhibitors that are mainly for cancer. Currently, these products are classified in L1H9 (Protein kinase inhibitor antineoplastics, other).

L1H7	Protein kinase inhibitor antineoplastics, JAK
	Includes products containing fedratinib, pacritinib, ruxolitinib, etc that are primarily for cancer. Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions, and in M1 if only for musculoskeletal conditions. Products containing JAK inhibitors to treat multiple immune conditions are classified in L4D.

JAK inhibitors – immune disorders

New third level class within L4 (Immunosuppressants) for products containing JAK inhibitors that are used for a variety of immune disorders. Currently, these products are classified in L4X (Other immunosuppressants).

L4D	JAK INHIBITORS
	<p>Includes products containing JAK inhibitors, eg baricitinib, filgotinib, tofacitinib, upadacitinib. These products are indicated for multiple conditions, eg rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis.</p> <p>Products containing JAK inhibitors primarily for cancer are classified in L1H7.</p> <p>Products containing JAK inhibitors are classified in A7 if only for gastro-intestinal conditions, in D5 if only for skin conditions, and in M1 if only for musculoskeletal conditions.</p>